These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

802 related items for PubMed ID: 24023329

  • 1. Incidence of bisphosphonate-related osteonecrosis of the jaw in consideration of primary diseases and concomitant therapies.
    Assaf AT, Smeets R, Riecke B, Weise E, Gröbe A, Blessmann M, Steiner T, Wikner J, Friedrich RE, Heiland M, Hoelzle F, Gerhards F.
    Anticancer Res; 2013 Sep; 33(9):3917-24. PubMed ID: 24023329
    [Abstract] [Full Text] [Related]

  • 2. The role of surgical resection in the management of bisphosphonate-related osteonecrosis of the jaws.
    Carlson ER, Basile JD.
    J Oral Maxillofac Surg; 2009 May; 67(5 Suppl):85-95. PubMed ID: 19371819
    [Abstract] [Full Text] [Related]

  • 3. Intravenous bisphosphonate-related osteonecrosis of the jaw: bone scintigraphy as an early indicator.
    O'Ryan FS, Khoury S, Liao W, Han MM, Hui RL, Baer D, Martin D, Liberty D, Lo JC.
    J Oral Maxillofac Surg; 2009 Jul; 67(7):1363-72. PubMed ID: 19531404
    [Abstract] [Full Text] [Related]

  • 4. Bisphosphonate-related osteonecrosis of the jaw: clinical features, risk factors, management, and treatment outcomes of 26 patients.
    Thumbigere-Math V, Sabino MC, Gopalakrishnan R, Huckabay S, Dudek AZ, Basu S, Hughes PJ, Michalowicz BS, Leach JW, Swenson KK, Swift JQ, Adkinson C, Basi DL.
    J Oral Maxillofac Surg; 2009 Sep; 67(9):1904-13. PubMed ID: 19686928
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate.
    Walter C, Al-Nawas B, Grötz KA, Thomas C, Thüroff JW, Zinser V, Gamm H, Beck J, Wagner W.
    Eur Urol; 2008 Nov; 54(5):1066-72. PubMed ID: 18602738
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Bisphosphonate-related osteonecrosis of the jaw in patients with oral bisphosphonate exposure: clinical course and outcomes.
    O'Ryan FS, Lo JC.
    J Oral Maxillofac Surg; 2012 Aug; 70(8):1844-53. PubMed ID: 22595135
    [Abstract] [Full Text] [Related]

  • 9. Incidence of maxillary sinusitis and oro-antral fistulae in bisphosphonate-related osteonecrosis of the jaw.
    Mast G, Otto S, Mücke T, Schreyer C, Bissinger O, Kolk A, Wolff KD, Ehrenfeld M, Stürzenbaum SR, Pautke C.
    J Craniomaxillofac Surg; 2012 Oct; 40(7):568-71. PubMed ID: 22118926
    [Abstract] [Full Text] [Related]

  • 10. Osteonecrosis of the jaw in Sweden associated with the oral use of bisphosphonate.
    Ulmner M, Jarnbring F, Törring O.
    J Oral Maxillofac Surg; 2014 Jan; 72(1):76-82. PubMed ID: 23992777
    [Abstract] [Full Text] [Related]

  • 11. A retrospective study evaluating frequency and risk factors of osteonecrosis of the jaw in 576 cancer patients receiving intravenous bisphosphonates.
    Thumbigere-Math V, Tu L, Huckabay S, Dudek AZ, Lunos S, Basi DL, Hughes PJ, Leach JW, Swenson KK, Gopalakrishnan R.
    Am J Clin Oncol; 2012 Aug; 35(4):386-92. PubMed ID: 22561331
    [Abstract] [Full Text] [Related]

  • 12. Intravenous bisphosphonate therapy and bisphosphonate-related osteonecrosis of the jaws.
    Dodson TB.
    J Oral Maxillofac Surg; 2009 May; 67(5 Suppl):44-52. PubMed ID: 19371814
    [Abstract] [Full Text] [Related]

  • 13. Osteonecrosis of the Jaw in Patients Receiving Bone-Targeted Therapies: An Overview--Part I.
    Turner B, Drudge-Coates L, Ali S, Pati J, Nargund V, Ali E, Cheng L, Wells P.
    Urol Nurs; 2016 May; 36(3):111-6, 154. PubMed ID: 27501591
    [Abstract] [Full Text] [Related]

  • 14. Osteonecrosis of the jaws in patients assuming oral bisphosphonates for osteoporosis: a retrospective multi-hospital-based study of 87 Italian cases.
    Di Fede O, Fusco V, Matranga D, Solazzo L, Gabriele M, Gaeta GM, Favia G, Sprini D, Peluso F, Colella G, Vescovi P, Campisi G.
    Eur J Intern Med; 2013 Dec; 24(8):784-90. PubMed ID: 23768563
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Is bone turnover of jawbone and its possible over suppression by bisphosphonates of etiologic importance in pathogenesis of bisphosphonate-related osteonecrosis?
    Ristow O, Gerngroß C, Schwaiger M, Hohlweg-Majert B, Kehl V, Jansen H, Hahnefeld L, Otto S, Pautke C.
    J Oral Maxillofac Surg; 2014 May; 72(5):903-10. PubMed ID: 24485975
    [Abstract] [Full Text] [Related]

  • 17. Does regular zoledronic acid change the bone turnover of the jaw in men with metastatic prostate cancer: a possible clue to the pathogenesis of bisphosphonate related osteonecrosis of the jaw?
    Ristow O, Gerngroß C, Schwaiger M, Hohlweg-Majert B, Ristow M, Koerdt S, Schuster R, Otto S, Pautke C.
    J Cancer Res Clin Oncol; 2014 Mar; 140(3):487-93. PubMed ID: 24469255
    [Abstract] [Full Text] [Related]

  • 18. A study of 225 patients on bisphosphonates presenting to the bisphosphonate clinic at King's College Hospital.
    Taylor T, Bryant C, Popat S.
    Br Dent J; 2013 Apr; 214(7):E18. PubMed ID: 23579162
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Oral bisphosphonates as a cause of bisphosphonate-related osteonecrosis of the jaws: clinical findings, assessment of risks, and preventive strategies.
    Assael LA.
    J Oral Maxillofac Surg; 2009 May; 67(5 Suppl):35-43. PubMed ID: 19371813
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 41.